IIM
AMLX icon

INTECH Investment Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

INTECH Investment Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$355K Sell
19,775
-5,146
-21% -$79.6K ﹤0.01% 1494
2026
Q1 		$346K Sell
24,921
-7,085
-22% -$99.7K ﹤0.01% 1503
2025
Q4 		$387K Buy
32,006
+12,512
+64% +$170K ﹤0.01% 1631
2025
Q3 		$265K Sell
19,494
-16,821
-46% -$158K ﹤0.01% 1903
2025
Q2 		$233K Buy
+36,315
New +$177K ﹤0.01% 2012

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

INTECH Investment Management's AMLX Position: Q2 2026 in Review

INTECH Investment Management reduced its Amylyx Pharmaceuticals (AMLX) stake by 21% in Q2 2026, selling an estimated $79.6K and leaving 19,775 shares worth $355K. The position accounts for ﹤0.01% of the portfolio, ranked #1494.

INTECH Investment Management first reported a position in AMLX in Q2 2025 and has held it in 5 quarters since. The position peaked at $387K in Q4 2025. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • INTECH Investment Management held 19,775 shares of Amylyx Pharmaceuticals worth $355K as of Q2 2026.
  • INTECH Investment Management sold 5,146 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $79.6K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of INTECH Investment Management's portfolio in Q2 2026, its #1494 holding.
  • INTECH Investment Management first reported a position in Amylyx Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • INTECH Investment Management's Amylyx Pharmaceuticals position peaked at $387K in Q4 2025.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.